Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Seung-Oe Lim"'
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Immunotherapy, powered by its relative efficacy and safety, has become a prominent therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer. Within this class of therapeutics, there is a variety of drug types such
Externí odkaz:
https://doaj.org/article/13c6887bec6847daa40ffea5cb7f7d19
Publikováno v:
Cells, Vol 11, Iss 1, p 162 (2022)
Leveraging the T cell immunity against tumors represents a revolutionary type of cancer therapy. 4-1BB is a well-characterized costimulatory immune receptor existing on activated T cells and mediating their proliferation and cytotoxicity under infect
Externí odkaz:
https://doaj.org/article/079cfcde8fcb402ebe65652c06b3ca92
Autor:
Jung-Mao Hsu, Weiya Xia, Yi-Hsin Hsu, Li-Chuan Chan, Wen-Hsuan Yu, Jong-Ho Cha, Chun-Te Chen, Hsin-Wei Liao, Chu-Wei Kuo, Kay-Hooi Khoo, Jennifer L. Hsu, Chia-Wei Li, Seung-Oe Lim, Shih-Shin Chang, Yi-Chun Chen, Guo-xin Ren, Mien-Chie Hung
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-17 (2018)
PD-L1 accumulates on cancer stem cells and favours immune evasion but the mechanism underlying this accumulation are unknown. Here the authors show that epithelial-mesenchymal transition induces glycosylation and stabilisation of PD-L1; antagonising
Externí odkaz:
https://doaj.org/article/b6e5e0697fa048aeb6392035c75e7d85
Publikováno v:
Cells, Vol 10, Iss 5, p 1100 (2021)
Evading host immune surveillance is one of the hallmarks of cancer. Immune checkpoint therapy, which aims to eliminate cancer progression by reprogramming the antitumor immune response, currently occupies a solid position in the rapidly expanding ars
Externí odkaz:
https://doaj.org/article/47026f144a3440728ac179bcc02aa383
Autor:
Chia-Wei Li, Seung-Oe Lim, Weiya Xia, Heng-Huan Lee, Li-Chuan Chan, Chu-Wei Kuo, Kay-Hooi Khoo, Shih-Shin Chang, Jong-Ho Cha, Taewan Kim, Jennifer L. Hsu, Yun Wu, Jung-Mao Hsu, Hirohito Yamaguchi, Qingqing Ding, Yan Wang, Jun Yao, Cheng-Chung Lee, Hsing-Ju Wu, Aysegul A. Sahin, James P. Allison, Dihua Yu, Gabriel N. Hortobagyi, Mien-Chie Hung
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-11 (2016)
Programmed Death ligand-1 (PD-L1) protein mediates immune suppression in cancer. Here, the authors show that in breast cancer, PD-L1 expression can be up regulated post-translationally by glycosylation, which in turn acts through inhibiting GSK3β-me
Externí odkaz:
https://doaj.org/article/95bbbbb825d74f9a9d75ce9718db0cfa
Autor:
Wonkyung Oh, Alyssa Min Jung Kim, Deepika Dhawan, Perry M. Kirkham, Raluca Ostafe, Jackeline Franco, Uma K. Aryal, Robert H. Carnahan, Valery Patsekin, J. Paul Robinson, Deborah W. Knapp, Seung-Oe Lim
Publikováno v:
Cancer Research Communications. 3:860-873
Immune checkpoint blockade therapy, one of the most promising cancer immunotherapies, has shown remarkable clinical impact in multiple cancer types. Despite the recent success of immune checkpoint blockade therapy, however, the response rates in pati
Abstract P3-07-24: Role of tumor cell-derived lactic acid in the PD-1/PD-L1 blockade resistant tumor
Autor:
Wonkyung Oh, Seung-Oe Lim
Publikováno v:
Cancer Research. 83:P3-07
Immune checkpoint blockade therapy targeting the PD-1/PD-L1 axis (PD-1/PD-L1 blockade therapy) has shown remarkable clinical impact in multiple cancer types. Despite the recent success of PD-1/PD-L1 blockade therapy, acquired resistance, emerging as
Autor:
Seung-Oe Lim, Deborah W. Knapp, J. Paul Robinson, Valery Patsekin, Robert H. Carnahan, Uma K. Aryal, Jackeline Franco, Raluca Ostafe, Perry M. Kirkham, Deepika Dhawan, Alyssa Min Jung Kim, Wonkyung Oh
Working flow chart for production and validation of the cPD-L1 antibody. A, Immunization of antigen, cPD-L1 protein. B, Establishment of hybridomas (over 2,000 clones). C, Evaluation of the cPD-L1 specific antibody by the live cell–based antibody b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f349bf5c084626a7d27c1d75041bb85
https://doi.org/10.1158/2767-9764.22822025
https://doi.org/10.1158/2767-9764.22822025
Autor:
Seung-Oe Lim, Deborah W. Knapp, J. Paul Robinson, Valery Patsekin, Robert H. Carnahan, Uma K. Aryal, Jackeline Franco, Raluca Ostafe, Perry M. Kirkham, Deepika Dhawan, Alyssa Min Jung Kim, Wonkyung Oh
Immune checkpoint blockade therapy, one of the most promising cancer immunotherapies, has shown remarkable clinical impact in multiple cancer types. Despite the recent success of immune checkpoint blockade therapy, however, the response rates in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08daf95a320ab4fd4835db28b003c9dc
https://doi.org/10.1158/2767-9764.c.6647231.v1
https://doi.org/10.1158/2767-9764.c.6647231.v1
Autor:
Seung-Oe Lim, Deborah W. Knapp, J. Paul Robinson, Valery Patsekin, Robert H. Carnahan, Uma K. Aryal, Jackeline Franco, Raluca Ostafe, Perry M. Kirkham, Deepika Dhawan, Alyssa Min Jung Kim, Wonkyung Oh
Evaluation of the caninized cPD-L1 chimeric antibody. A, 12C antibody binding on the BT549cPD-L1 cells. B, Flow cytometric analysis of the 12C chimeric antibody on the BT549cPD-L1 cells. cIgG serves as a negative control. C, 12C chimeric antibody bin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29171929ccf015f96aff9b1869cb5934
https://doi.org/10.1158/2767-9764.22822010.v1
https://doi.org/10.1158/2767-9764.22822010.v1